Urgent Updates | February 23

Even One Head Injury Boosts All-Cause Mortality Risk
Sustaining even a single head injury has been linked to a significantly increased risk of all-cause mortality. An analysis of more than 13,000 adult participants in the Atherosclerosis Risk in Communities (ARIC) study showed a dose-response pattern in which one head injury was linked to a 66% increased risk for all-cause mortality, and two or more head injuries were associated with twice the risk in comparison with no head injuries.
Full Access: Medscape

Hundreds more physicians died than expected amid pandemic
Just as COVID-19 led to a much higher number of deaths for the public than what would have been anticipated without the virus, during the same time physicians in the workforce saw more than 600 excess deaths among their profession. Data from the AMA was used by researchers from Stanford (Calif.) University School of Medicine and the AMA itself to calculate the number of excess physician deaths between March 2020 and December 2021, finding 622 more deaths than expected.
Full Access: Becker’s Hospital Review

Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study
This multicenter prospective cohort study of adults with acute illness tested for SARS-CoV-2 compared fatigue severity, fatigue symptoms, individual and organ system-based symptoms, and presence of ≥3 total symptoms across variants among COVID-positive and COVID-negative participants 3 months after their initial SARS-CoV-2 diagnosis. Prolonged symptoms following SARS-CoV-2 infection were more common among participants infected during the pre-Delta period compared with Delta and Omicron periods; however, these differences were no longer significant after adjusting for vaccination status.
Full Access: Clinical Infectious Diseases

Probiotic for pathogen-specific decolonization in Thailand: a phase 2, double-blind, randomized, placebo-controlled trial
This single-center, phase 2, double-blind, randomized, placebo-controlled trial in adults in Thailand who were colonized by S aureus. Participants received 250 mg of probiotic B subtilis MB40 or placebo once per day for 30 days and S aureus colonization was determined after the last dose was received. B subtilis probiotic eliminated more than 95% of the total S aureus colonizing the human body without altering the microbiota. This probiotic strategy offers several key advantages over presently used decolonization strategies for potential use in people with chronic or long-term risk of S aureus infection.
Full Access: The Lancet